Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sarepta Therapeutics Names Jean-Paul Kress To Board

This article was originally published in Scrip

Executive Summary

Sarepta Therapeutics, a company developing RNA-targeted therapies, has appointed Jean-Paul Kress to its board of directors. Kress is currently head of Sanofi Genzyme speciality care business unit in North America and before this he was president and CEO of Sanofi Pasteur MSD.Previously, Kress was at Gilead as vice-president and general manager in France.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC029937

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel